IL-33, sST2, and CRP in Panic Disorder
Recruiting · NCT07444879 · Observational (researchers observe without assigning treatment) · Lead sponsor: Elazığ Mental Health and Diseases Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
Who can take part
Inclusion criteria
- Being between 18-65 years of age
- Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
- Not having previously used any medication for psychiatric purposes (drug-naive)
- Not having any additional active psychiatric disorders besides PD at the current presentation
- Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Not having taken any medication or supplements in the last month
- Completing sociodemographic and scale data fully
- Volunteering to participate in the study
- For PD Group:
Exclusion criteria
- Being outside the 18-65 age range
- Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health
- Having a history of psychiatric medication use
- Having an additional psychiatric disorder besides PD at the current application
- Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer
- Patients with a body mass index (BMI) \<18.5 kg/m² and \>29.9 kg/m²
- Taking any medication or supplement in the last month
- Incomplete completion of sociodemographic and scale data
- Not volunteering to participate in the study
- For Healthy Control Group:
- Inclusion Criteria:
- Being between 18-65 years of age
- Not having any active psychiatric disorder
- Not having previously used any medication for psychiatric purposes (drug-naive)
- Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Not having taken any medication or supplement in the last month
- Completing sociodemographic and scale data fully
- Volunteering to participate in the study
- For Healthy Control Group:
- \*Exclusion Criteria:
- Being outside the 18-65 age range
- Having any active psychiatric disorder
- Having a history of using psychiatric medication
- Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Patients with a body mass index (BMI) \< 18.5 kg/m² and \> 29.9 kg/m²
- Taking any medication or supplement in the last month
- Incomplete completion of sociodemographic and scale data
- Not volunteering to participate in the study
Where it is running
1 location listed.
- Elazığ Mental Health and Diseases Hospital Psychiatry Clinic - Elâzığ, Elâzığ, Turkey (Türkiye)